![]() |
Short Contents | Full Contents | Other books NCBI |
|
AHRQ Evidence reports and summaries ![]() 89. Effects of Omega-3 Fatty Acids on Lipids and Glycemic Control in Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal Disease, Systemic Lupus Erythematosus, and Osteoporosis Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 Contract No. 290-02-0003 Prepared by: Southern California/RAND Evidence-based Practice Center, Los Angeles, CA Program Directors Paul G. Shekelle, MD, PhD Sally C. Morton, PhD Project Director Catherine H. MacLean, MD, PhD Project Manager Rena Hasenfeld Garland, BA Statistician Wenli Tu, MS Programmer/Analyst Lara K. Jungvig, BA Scientific Reviewers Walter A. Mojica, MD, MPH James Pencharz, BSc (Kin) Jennifer Grossman, MD Puja Khanna, MD, MPH Editor Sydne J. Newberry, PhD Technical Advisors Ian Gralnek, MD, mshs Alan Nissenson, MD Librarians Jessie McGowan, MLIS Nancy Santesso, RD, MLIS Staff Assistants Donna Mead, BA Shannon Rhodes, MFA Shana Traina, MA AHRQ Publication No. 04-E012-2 March 2004 ISBN: 1-58763-141-5 ISSN: 1530-4396 This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. AHRQ is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services. AHRQ sponsors and conducts research that provides evidence-based information on health care outcomes; quality; and cost, use, and access. The information helps health care decisionmakers Suggested Citation: MacLean CH, Mojica, WA, Morton SC, Pencharz J, Hasenfeld Garland R, Tu W, Newberry SJ, Jungvig LK, Grossman J, Khanna P, Rhodes S, Shekelle P. Effects of Omega-3 Fatty Acids on Lipids and Glycemic Control in Type II Diabetes and the Metabolic Syndrome and on Inflammatory Bowel Disease, Rheumatoid Arthritis, Renal Disease, Systemic Lupus Erythematosus, and Osteoporosis. Evidence Report/Technology Assessment. No. 89 (Prepared by Southern California/RAND Evidence-based Practice Center, under Contract No. 290-02-0003). AHRQ Publication No. 04-E012-2. Rockville, MD: Agency for Healthcare Research and Quality. March 2004. |